Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma
Clinical trial NCT03095079 · UNKNOWN
Trial details
- NCT number
- NCT03095079
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-01
- Primary completion
- 2017-12-01
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.